Most Read Articles
14 Dec 2017
The coexistence of fibromyalgia in patients with axial spondyloarthritis (axSpA) exerts a negative effect on response to tumour necrosis factor blocker, according to a study. This effect appears to be associated with the self-reported instruments used in fibromyalgia evaluation rather than a different treatment effect of the agent in this population.

Osteoporosis highly prevalent in COPD patients

08 Aug 2019

The prevalence of osteoporosis among patients with chronic obstructive pulmonary disease (COPD) appears to be high and similar in many countries, according to the results of a meta-analysis.

Researchers searched multiple online databases for studies reporting the prevalence and risk factors for osteoporosis in COPD. Two reviewers conducted eligibility screening, data extraction and quality assessment of the retrieved articles.

The meta-analysis included 58 studies. Pooled global prevalence of osteoporosis in COPD was 38 percent (95 percent CI, 34–43). The likelihood of having the bone disease increased by more than twofold in the presence of COPD (odds ratio [OR], 2.83).

Additional significant risk factors for osteoporosis in COPD patients were low body mass index (<18.5 kg/m2; OR, 4.26) and the presence of sarcopenia (OR, 3.65).

The present data suggest that COPD patients should be regularly screened for osteoporosis and contributing risk factors, the researchers said.

Osteoporosis is one of the major systemic comorbidities of COPD and is associated with significant morbidity. Factors implicated in the pathogenesis of the bone disease include systemic inflammatory, physical inactivity, body composition changes, tobacco exposure, corticosteroids use, hypogonadism, anaemia, COPD exacerbation and hypoxia. [Int J Chron Obstruct Pulmon Dis 2016;11:637-648; Clin Med Insights Circ Respir Pulm Med 2015;9:5-21]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
14 Dec 2017
The coexistence of fibromyalgia in patients with axial spondyloarthritis (axSpA) exerts a negative effect on response to tumour necrosis factor blocker, according to a study. This effect appears to be associated with the self-reported instruments used in fibromyalgia evaluation rather than a different treatment effect of the agent in this population.